Stefan Zeuzem, MD, PhD

Department of Medicine, University Hospital Frankfurt, Frankfurt am Main, Germany
Frankfurt, Hessen, Germany

Disclosure(s): AbbVie: Advisor/Consultant, speaker bureau; Allergan: Advisor/Consultant, speaker bureau; BioMarin: Advisor/Consultant, speaker bureau; Gilead Sciences, Inc.: Advisor/Consultant, speaker bureau; Intercept: Advisor/Consultant, speaker bureau; Janssen: Advisor/Consultant, speaker bureau; Merck Sharp & Dohme: Advisor/Consultant, speaker bureau; Novo Nordisk: Advisor/Consultant, speaker bureau; Swedish Orphan Biovitrum: Advisor/Consultant, speaker bureau; Theratechnologies: Advisor/Consultant, speaker bureau

Presentation(s):

• 521 - Efficacy and safety of buleviritide monotherapy for chronic hepatitis D in patients with and without cirrhosis: results from the week 144 interim analysis of a phase 3 randomized study

  Saturday, October 19, 2024
  12:20 PM – 12:25 PM US PT